SCHEMBL3398994

SCHEMBL3398994

Cc1cc2cnc(Cl)nc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
BRD4 O60885 1/20 0.37
MAP4K1 Q92918 2/20 0.35
PIK3CG P48736 1/20 0.35
JUN P05412 2/20 0.34
NFKB1 P19838 2/20 0.34
NFKB2 Q00653 2/20 0.34
RELA Q04206 2/20 0.34
PLK4 O00444 1/20 0.33
PAK4 O96013 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
XPO1 O14980 1/20 0.31
EGFR P00533 1/20 0.31
DAO P14920 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890136 0.79 PDK2 (0.40) KDM4EBRD4MAP4K1PIK3CGADORA2A
SCHEMBL29133962 0.79 TYRO3 (0.50) TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL30661283 0.79 TYRO3 (0.50) TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL20683899 0.76 TYRO3 (0.43) TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL13188456 0.76 MAP4K1 (0.38) KDM4EBRD4MAP4K1ADORA2AADORA1
SCHEMBL25831728 0.76 BRD4 (0.40) TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL13154919 0.73 BRD4 (0.36) KDM4EBRD4MAP4K1ADORA2AADORA1
SCHEMBL25909820 0.72 FGFR2 (0.42) ALDH1A1SMN1; SMN2NFKB1NFKB2RELA
SCHEMBL2041171 0.72 BRD4 (0.47) ALDH1A1BRD4MAP4K1PIK3CG
SCHEMBL30292438 0.72 HTT (0.40) TYRO3DYRK1BKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 US disclosed
WO-2023217201-A2 NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF 杭州德睿智药科技有限公司 2023-11-16 WO disclosed
US-11717523-B2 Transient protection of normal cells during chemotherapy G1 THERAPEUTICS, INC. (US) 2023-08-08 US disclosed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 EP disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK6 TYRO3 3315/4885DYRK1B 1349/4885KDM4E 945/4885
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 TYRO3 61/4885DYRK1B 915/4885KDM4E 1741/4885
US-11717523-B2 Transient protection of normal cells during chemotherapy CDK6, CCNC, MCL1 TYRO3 4284/4885DYRK1B 2202/4885KDM4E 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.